Literature DB >> 10050727

Syndecan-1 (CD138) expression in human non-Hodgkin lymphomas.

A Sebestyén1, L Berczi, R Mihalik, S Paku, A Matolcsy, L Kopper.   

Abstract

Syndecan-1, an important transmembrane heparan sulphate proteoglycan is expressed in distinct stages of differentiation of normal lymphoid cells: in pre-B cells and Ig-producing plasma cells; however, its normal function, or presence in lymphoid malignancies, is still largely unknown. The expression of syndecan-1 (CD138) was studied in 57 human non-Hodgkin lymphomas using immunocytochemistry and immunohistochemistry. Positive expression of syndecan-1 was found in the plasma cells in chronic lymphoblastic leukaemia (B-CLL) cases, in different plasmocytoid lymphomas as well as in myeloma. All normal and malignant Tcells, or CD5+ cells other than B-CLL proved to be negative. These results strongly suggest that syndecan-1 expression is a characteristic phenotypic marker for B-CLL and lymphoplasmocytoid lymphomas and could be used for diagnostic purposes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10050727     DOI: 10.1046/j.1365-2141.1999.01211.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  12 in total

Review 1.  Insights into the molecular roles of heparan sulfate proteoglycans (HSPGs-syndecans) in autocrine and paracrine growth factor signaling in the pathogenesis of Hodgkin's lymphoma.

Authors:  Rajendra Gharbaran
Journal:  Tumour Biol       Date:  2016-06-18

2.  Specific in situ visualization of plasma cells producing antibodies against Porphyromonas gingivalis in gingival radicular cyst: application of the enzyme-labeled antigen method.

Authors:  Shinya Tsuge; Yasuyoshi Mizutani; Kazuhiro Matsuoka; Tatsuya Sawasaki; Yaeta Endo; Koji Naruishi; Hiroshi Maeda; Shogo Takashiba; Kazuya Shiogama; Ken-Ichi Inada; Yutaka Tsutsumi
Journal:  J Histochem Cytochem       Date:  2011-04-27       Impact factor: 2.479

3.  Soluble CD138 serum levels are not associated with other poor prognostic markers in patients with B-chronic lymphocytic leukaemia.

Authors:  A Alonci; A Allegra; G Bellomo; A D'Angelo; G Penna; A Cannavò; C Musolino
Journal:  Med Oncol       Date:  2009-12-16       Impact factor: 3.064

4.  The proteoglycan repertoire of lymphoid cells.

Authors:  Bodil Fadnes; Anne Husebekk; Gunbjørg Svineng; Øystein Rekdal; Masaki Yanagishita; Svein O Kolset; Lars Uhlin-Hansen
Journal:  Glycoconj J       Date:  2012-07-10       Impact factor: 2.916

Review 5.  Proteoglycans in cancer biology, tumour microenvironment and angiogenesis.

Authors:  Renato V Iozzo; Ralph D Sanderson
Journal:  J Cell Mol Med       Date:  2011-05       Impact factor: 5.310

6.  Circulating sCD138 and some angiogenesis-involved cytokines help to anticipate the disease progression of early-stage B-cell chronic lymphocytic leukemia.

Authors:  Dariusz Wołowiec; Jarosław Dybko; Tomasz Wróbel; Donata Urbaniak-Kujda; Bozena Jaźwiec; Beata Tomaszewska-Toporska; Katarzyna Kapelko-Słowik; Stanisław Potoczek; Kazimierz Kuliczkowski
Journal:  Mediators Inflamm       Date:  2006       Impact factor: 4.711

Review 7.  Syndecan-1 in Cancer: Implications for Cell Signaling, Differentiation, and Prognostication.

Authors:  Tünde Szatmári; Rita Ötvös; Anders Hjerpe; Katalin Dobra
Journal:  Dis Markers       Date:  2015-09-01       Impact factor: 3.434

8.  Fibroblast growth factor-2 (FGF2) and syndecan-1 (SDC1) are potential biomarkers for putative circulating CD15+/CD30+ cells in poor outcome Hodgkin lymphoma patients.

Authors:  Rajendra Gharbaran; Andre Goy; Takemi Tanaka; Jongwhan Park; Chris Kim; Nafis Hasan; Swathi Vemulapalli; Sreeja Sarojini; Madalina Tuluc; Kip Nalley; Pritish Bhattacharyya; Andrew Pecora; K Stephen Suh
Journal:  J Hematol Oncol       Date:  2013-08-29       Impact factor: 17.388

Review 9.  Syndecans as modulators and potential pharmacological targets in cancer progression.

Authors:  Despoina Barbouri; Nikolaos Afratis; Chrisostomi Gialeli; Demitrios H Vynios; Achilleas D Theocharis; Nikos K Karamanos
Journal:  Front Oncol       Date:  2014-02-03       Impact factor: 6.244

10.  Proteoglycan expression correlates with the phenotype of malignant and non-malignant EBV-positive B-cell lines.

Authors:  Alexandra Y Tsidulko; Liudmila Matskova; Lidiia A Astakhova; Ingemar Ernberg; Elvira V Grigorieva
Journal:  Oncotarget       Date:  2015-12-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.